CG Oncology (NASDAQ:CGON) Director James Mulay Sells 24,165 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 24,165 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the transaction, the director directly owned 24,165 shares of the company’s stock, valued at $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

James Mulay also recently made the following trade(s):

• On Monday, June 15th, James Mulay sold 1,964 shares of CG Oncology stock. The shares were sold at an average price of $60.12, for a total transaction of $118,075.68.
• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00.

CG Oncology Trading Down 1.0%

NASDAQ:CGON opened at $71.77 on Wednesday. CG Oncology, Inc. has a 12 month low of $23.65 and a 12 month high of $77.00. The company has a market cap of $6.33 billion, a PE ratio of -30.80 and a beta of 0.22. The company has a 50 day simple moving average of $65.12 and a two-hundred day simple moving average of $60.78.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. Research analysts forecast that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Institutional Trading of CG Oncology

Several hedge funds have recently bought and sold shares of CGON. Wellington Management Group LLP raised its stake in shares of CG Oncology by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of CG Oncology by 116.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after acquiring an additional 1,854,386 shares during the period. State Street Corp increased its holdings in CG Oncology by 46.4% in the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after acquiring an additional 950,028 shares in the last quarter. Alliancebernstein L.P. increased its holdings in CG Oncology by 15.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after acquiring an additional 281,637 shares in the last quarter. Finally, RTW Investments LP raised its stake in CG Oncology by 18.3% during the 4th quarter. RTW Investments LP now owns 2,012,127 shares of the company’s stock worth $83,544,000 after acquiring an additional 310,911 shares during the period. Institutional investors own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wolfe Research initiated coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Royal Bank Of Canada boosted their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Wedbush raised their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.